Nature Medicine covers MIMETAS and OrganoPlate
Channeling chip power: Tissue chips are being put to the test by industry
February 2017. Nature Medicine covers MIMETAS and OrganoPlate® in an article entitled "Channeling chip power: Tissue chips are being put to the test by industry" by Cassandra Willyard.
“By co-developing them [ed. organs-on-chips], we make sure that we develop the models that they want and we transfer them into their [ed. the pharma companies'] hands,” says Jos Joore, co-founder of Mimetas, a biotech company based in the Netherlands that is working on several tissue chips. Collaborating with companies such as GlaxoSmithKline and Pfizer also gives Mimetas access to compounds that never reached the market. The chip developers receive the failed compounds in tandem with preclinical and clinical data that would not otherwise be publicly available—data that can then help developers to improve the chip model.
Scalability is a hurdle, but is it?
Claire Jeong, a working-group member and GlaxoSmithKline investigator who works on in vitro models, points at the hurdle of scalability. “If this [ed.: organ-on-a-chip] device is really great, but only one lab can make one device per month, we are not going to be interested,” she says in the article. The OrganoPlate® platform is designed to overcome these limitations, with 40-96 tissue chips on a fully compatible 384-well plate format.
Link to the article (behind a paywall)